|Bid||4.8000 x 900|
|Ask||5.0100 x 1100|
|Day's Range||4.8000 - 5.1200|
|52 Week Range||3.1400 - 12.4700|
|Beta (5Y Monthly)||1.63|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||20.00|
PHILADELPHIA and VANCOUVER, British Columbia, May 18, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announces that it has activated Hoag Memorial Hospital Presbyterian (“Hoag”) and re-engaged Sylvester Comprehensive Cancer Center, part of UHealth – the University of Miami Health System, as two additional clinical sites
We can readily understand why investors are attracted to unprofitable companies. Indeed, BriaCell Therapeutics...
Announced that the U.S. Food and Drug Administration has granted Fast Track status to BriaCell’s lead ...